Foundation Medicine announced it is launching a liquid biopsy test for solid tumours as it expands its range of blood-based gene sequencing tools. The test, called FoundationOne Liquid, uses two tubes of blood to identify genetic alterations from DNA fragments which have been shed by tumours, allowing the company to detect the cause of the tumour's growth. Foundation, which is aiming to receive FDA approval in the near future, made the new test available to selected doctors early September but has now officially expanded its availability to all physicians for $5,800.
Foundation Medicine announced it is launching a liquid biopsy test for solid tumours as it expands its range of blood-based gene sequencing tools. The test, called FoundationOne Liquid, uses two tubes of blood to identify genetic alterations from DNA fragments which have been shed by tumours, allowing the company to detect the cause of the tumour's growth. Foundation, which is aiming to receive FDA approval in the near future, made the new test available to selected doctors earlier this month but has now officially expanded its availability to all physicians for $5,800.